6/10/2022 6:07:58 AM
Amarin Gets Positive Recommendation From UK's NICE For Reimbursement Of VAZKEPA
5/24/2022 7:30:33 AM
HLS Therapeutics Gets Public Reimbursement For Vascepa In Quebec
11/3/2021 6:29:00 AM
Amarin Q3 Loss Per Share $0.03 Vs Loss $0.02 Last Year
4/17/2021 1:50:34 PM
Amarin Presents Further Analyses Of Icosapent Ethyl On Progression Of Coronary Atherosclerosis In EVAPORATE Trial
3/30/2021 6:39:46 AM
Amarin Says European Commission Approved Marketing Authorization Application For VAZKEPA
1/28/2021 6:42:55 AM
VASCEPA Gets Inclusions In Guidelines From Int'l Medical Societies For Role In Reducing Risk Of Cardiovascular Events
1/25/2021 7:46:00 PM
Amarin Expands Cardiovascular Risk Reduction Patent Infringement Lawsuit To Include Health Care Insurance Provider
1/7/2021 6:07:00 AM
Amarin Sees 2020 Total Net Revenue To Be About $610 Mln
4/6/2018 8:49:30 AM
Jefferies Is Cutting Amarin Corp Plc (AMRN) 2020 Estimate To -0.01 From 0.03
4/6/2018 8:49:05 AM
Jefferies Is Lowering Amarin Corp Plc (AMRN) 2019 Estimate To -0.33 From -0.05
4/6/2018 8:48:45 AM
Jefferies Is Cutting Amarin Corp Plc (AMRN) 2018 Estimate To -0.33 From -0.32